If the Phase I trial is successful, Moderna plans to quickly initiate Phase II and Phase III trials of its Ebola vaccine.
Moderna has initiated a Phase I trial of its mRNA Ebola vaccine for the Bundibugyo variant, just as Africa is readying itself for research.
The first-in-human Phase I trial (NCT07737717), which will test Moderna’s vaccine candidate, mRNA-1469, has been approved by Health Canada. The study will take place at three sites in Canada and evaluate the safety, tolerability and immunogenicity of the mRNA vaccine in healthy adult participants. The study is expected to enrol approximately 80 participants.
Moderna’s mRNA-1469 is designed to prevent Bundibugyo ebolavirus disease. The candidate is being developed using the company’s mRNA platform that was used to build its successful vaccine during the Covid-19 pandemic.
Stéphane Bancel, CEO of Moderna, said: “Vaccinating the first participants with mRNA-1469 marks an important milestone in advancing a vaccine candidate against Bundibugyo ebolavirus, for which no approved vaccine currently exists.”
mRNA-1469 is being advanced under Moderna’s expanded strategic collaboration with Coalition for Epidemic Preparedness Innovations (CEPI), which has committed up to $50m to support preclinical testing and the Phase I clinical trial.
Moderna said it hopes to initiate larger Phase II and Phase III studies quickly, should the Phase I data support further development.
Bundibugyo is one of the viruses that can cause Ebola disease and has been responsible for the active outbreak in the Democratic Republic of the Congo. Although vaccines are available against Zaire ebolavirus, no vaccine is currently approved to protect against disease caused by Bundibugyo.
The current outbreak was declared a Public Health Emergency of International Concern (PHEIC) and a Public Health Emergency of Continental Security (PHECS) by the World Health Organization (WHO) and Africa Centres for Disease Control and Prevention (Africa CDC), respectively. It has already caused more than 3,000 confirmed cases and more than 1,400 deaths, making it one of the largest filovirus outbreaks in history.
Dr Richard Hatchett, CEPI’s CEO, said: “This fast-growing epidemic is already the second-largest Ebola outbreak in history, and cases are rising more quickly than they did in the 2014 – 2016 West Africa epidemic, which remains the largest on record. Every day matters, and every vaccine candidate in clinical trials gives us another shot at getting a safe, effective vaccine to the people who need it as swiftly as possible.”
If licensed, Moderna said it is committed to enabling rapid supply and access to its Bundibugyo vaccine for affected countries and the populations that need it. As part of its agreement with CEPI, Moderna will make available at least 500,000 doses for timely supply to low- and middle-income countries at access pricing.
Africa readies itself for Bundibugyo research
Moderna’s Phase I initiation was announced at the same time that the Africa CDC and the CEPI confirmed the continent’s capability to conduct Phase I trials to accelerate development of safe, effective Bundibugyo ebolavirus vaccines.
The institutions published a database of comprehensive information on 45 African clinical trial units across 17 African countries.
Dr Jean Kaseya, Director-General of Africa CDC, said: “Africa has the scientific expertise, infrastructure and leadership to drive vaccine research on the continent. This database gives developers a clear pathway to experienced African clinical trial sites and enables faster action when every day matters. Africa CDC is committed to building a research ecosystem that protects our people, strengthens health security and places African institutions at the centre of solutions to Africa’s health emergencies.”
Clinical trials capacity in Africa has been built over time through partnerships between African research institutions, governments and partners in the clinical research ecosystem. Still, less than 5% of trials are conducted on the continent, despite it being home to nearly 20% of the world’s population.
Image Credit: Kitsawet Saethao / Shutterstock.com
News – Curated by Amanda Scott, Alias Group Creative
Follow her on Bluesky
Moderna kicks off Phase I Ebola trial as Africa readies itself for research
If the Phase I trial is successful, Moderna plans to quickly initiate Phase II and Phase III trials of its Ebola vaccine. Moderna has initiated a Phase I trial of its mRNA Ebola vaccine [...]
3D Human Brain Tissue Model Replicates Alzheimer’s Pathology
Summary: Researchers introduced a highly reproducible three-dimensional human brain tissue model capable of replicating complex neurodegenerative processes in Alzheimer’s disease. Developed over nine years using human stem cells, the self-organizing tissue spheroids integrate functional neurons, [...]
A Common Sugar May Loosen Cancer Cells and Help Them Spread
Chemotherapy may kill most ovarian cancer cells, but the few that survive can turn dangerously active. By releasing fructose, they may help nearby tumor cells break free and spread. Researchers at The Wistar Institute [...]
COVID-19 can wake up dormant viruses in the body, large study confirms
Virus reactivations by SARS-CoV-2 could worsen initial symptoms and increase risk of Long Covid. Early in the COVID-19 pandemic, scientists noticed that a SARS-CoV-2 infection can “wake up” other, dormant viruses already present in [...]
Scientists Discover the Brain May Enter a New Biological Phase Between 50 and 75
A single-cell study reveals major changes in immune cells, genome organization, and gene regulation within the aging human hippocampus, offering important insights into brain aging and dementias associated with age. Between roughly ages 50 [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Unzipping the Code of Life: Scientists Pinpoint Where DNA First Opens
Researchers mapped where DNA first opens and how a helicase gate may release one strand as genome copying begins. Before a cell can divide, it must open its tightly wound DNA and begin copying the entire [...]
Scientists Tested an 8-Hour Eating Window and Found a Surprising Brain Benefit
Limiting the daily eating window may provide brain benefits beyond those associated with weight loss. Eating within a shorter daily window may provide cognitive benefits beyond those associated with weight loss alone, according to [...]
Focused Ultrasound Opens Blood-Brain Barrier to Treat Brain Cancer
Summary: A new study demonstrates that primary brain tumors (gliomas) are particularly receptive to targeted drug delivery using focused ultrasound (FUS) combined with microbubbles. The team developed a high-resolution MRI protocol to track blood-brain barrier [...]
AI’s promise and practical limits in drug discovery
AI tools are becoming increasingly common in early drug discovery, allowing scientists to analyse data and navigate large volumes of research. However, according to Dr Raminderpal Singh, turning that potential into consistent scientific workflows [...]
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
Healthcare Headlines: Challenges and Advances in 2026
Health-related updates reveal financial adjustments by Universal Health Services due to Medicaid reimbursement uncertainties, significant pollution-linked health concerns from French-British oil firm Perenco in Congo, drug trial setbacks, potential restructuring at major medical firms, [...]
Scientists Discover the Brain Protein That Helps Alzheimer’s Spread Through the Brain
Scientists have identified a brain protein that may help Alzheimer’s spread, revealing a potential new target for slowing the disease’s progression. Alzheimer’s disease is closely linked to the accumulation of a toxic form of the protein [...]
How Immune Dysregulation Contributes to Psychiatric Disorders
Introduction Growing evidence suggests that disruptions in immune function may play an important role in the development and progression of psychiatric disorders. However, immune mechanisms probably contribute more strongly in some patients than others, [...]
Electrostatic Discharge Boosts Triboelectric Nanogenerator Current and Enables DC Output
Controlled electrical discharges could enable triboelectric nanogenerators to achieve higher peak currents, extending nano-enabled energy harvesting into chemical processing and self-powered sensing. Paper: Electrostatic discharge as a breakthrough strategy for triboelectric nanogenerators. A new review [...]
Swiss laboratory uses old drugs against rare diseases
Researchers at the University of Geneva are combing through collections of approved drugs to find new therapies for rare diseases – with some success. This approach is gaining traction around the world, while pharmaceutical [...]
